Exonic mutations in genes such as TP53 and EGFR, although well-established and thought of as key clinically-actionable mutations leading to recurrence and progression, were found in our cohort primarily as later events with respect to GBM phylogeny, as evidenced by their presence on both branches of the evolutionary tree and absence on its trunk. The gene discussed is TP53; the disease is glioblastoma.